
|Videos|February 10, 2016
Dr. David Reardon on Immunotherapy and Rindopepimut in the Glioblastoma Treatment Paradigm
Author(s)David Reardon, MD
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm.
Advertisement
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm. Reardon says rindopepimut is the first immunotherapy to ever show a survival benefit in glioblastoma and hopes a randomized phase III double blind trial with a placebo control arm will allow the drug to make bigger strides in the treatment of the malignancy.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































